Brain tumour patients at Coventry NHS trust given years of unnecessary chemotherapy, report finds

NHS trust chemotherapy brain tumour patients report, Digimart Global (Coventry, England): Cancer patients were severely harmed after receiving years of unnecessary chemotherapy from an NHS trust, according to a Royal College of Physicians (RCP) report. Some people were misdiagnosed and given inappropriate courses of treatment, while others were wrongly told that they would die if they stopped chemotherapy.

The report examined the treatment of brain tumour patients at University Hospitals Coventry and Warwickshire NHS trust. It was commissioned after concerns were raised by colleagues of Prof Ian Brown, a clinical oncologist who retired in 2023 and whose patients were then handed over to other clinicians.

The RCP found that patients had been kept on long-term repeated cycles of the chemotherapy drug temozolomide (TMZ), far longer than the usual course, without evidence that continuing it would benefit them. Some had remained on treatment even after their cancer progressed, when moving to supportive care for symptoms would have been a better choice.

The report reviewed 20 patients. Fifteen were found to have received unsatisfactory care and five were graded as requiring improvement.

One patient had more than 10 years of chemotherapy after being told they had glioblastoma, which was later found to be a grade-1 pilocytic astrocytoma, a low-grade tumour that does not require chemotherapy. Another experienced significant toxicity, including fatigue, nausea, and severe shingles requiring hospital admission.

The report says the trust should ensure that all living patients treated with more than 12 cycles of TMZ have had their case independently reviewed. Legal firm Brabners, which represents more than 40 patients, is calling for an independent public inquiry.

Becky Jones, who received more than 100 cycles of chemotherapy over 10 years after being incorrectly diagnosed with grade-4 glioblastoma, said that seeing the failings confirmed was “validating” but “incredibly painful”. “I now need a full and honest explanation of what happened to me,” she said.

Prof Andy Hardy, the trust’s chief executive, and Sue Noyes, its chair, said they were “deeply sorry” to the patients and families affected. They said the findings raise serious questions about individual clinical decisions and historical governance, and that the trust will learn from them openly and with the utmost urgency.

Freya Sullivan

Freya Sullivan covers British politics, parliamentary affairs, government policies, and economic developments. Her reporting explores major decisions, business trends, and public policy issues shaping the United Kingdom's political and economic landscape.

Leave a Reply

Your email address will not be published. Required fields are marked *

Sports

Explore Digimart Global